Biotech’s idea for a better ACL treatment gets funding from NFL players union

A torn ACL, the tiny band of tough connective tissue in the center of the knee, has marked the downfall of many a football star. Remember the running backs Terrell Davis of the Denver Broncos and Jamal Anderson of the Atlanta Falcons?

On Monday, a privately held biotech startup in Boston said it has raised $22.5 million to continue developing its new treatment for the often devastating injury. Among the investors: the union that represents National Football League players.

Dr. Martha Murray, the founder of MIACH Orthopaedics Inc. and an orthopedic surgeon in sports medicine at Boston Children’s Hospital, said the new technology “has the potential to transform connective tissue repair.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In